A University of Basel study published in Nature Communications reveals novel intracellular mechanisms restricting antisense oligonucleotide (ASO) therapies' effectiveness and identifies strategies to enhance their intracellular transport. By understanding and modulating cellular trafficking pathways, researchers aim to improve RNA-based drug delivery and therapeutic outcomes. These insights advance the clinical potential of RNA drugs by overcoming key biological barriers impeding their function.